Capital Analysts LLC Raises Position in Labcorp Holdings Inc. $LH

Capital Analysts LLC raised its holdings in Labcorp Holdings Inc. (NYSE:LH) by 1.8% in the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 17,153 shares of the medical research company’s stock after buying an additional 301 shares during the period. Capital Analysts LLC’s holdings in Labcorp were worth $3,992,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Golden State Wealth Management LLC boosted its position in Labcorp by 88.1% in the 1st quarter. Golden State Wealth Management LLC now owns 111 shares of the medical research company’s stock valued at $26,000 after buying an additional 52 shares during the period. North Capital Inc. acquired a new stake in shares of Labcorp in the 1st quarter valued at $27,000. TruNorth Capital Management LLC acquired a new stake in shares of Labcorp in the 1st quarter valued at $28,000. Larson Financial Group LLC raised its holdings in shares of Labcorp by 140.4% in the 1st quarter. Larson Financial Group LLC now owns 125 shares of the medical research company’s stock valued at $29,000 after purchasing an additional 73 shares in the last quarter. Finally, Financial Gravity Asset Management Inc. acquired a new stake in shares of Labcorp in the 1st quarter valued at $31,000. Hedge funds and other institutional investors own 95.94% of the company’s stock.

Labcorp Price Performance

Shares of NYSE:LH opened at $277.9550 on Thursday. The company’s fifty day moving average price is $260.53 and its 200 day moving average price is $247.66. Labcorp Holdings Inc. has a 12 month low of $209.38 and a 12 month high of $283.47. The company has a debt-to-equity ratio of 0.61, a current ratio of 1.50 and a quick ratio of 1.32. The firm has a market capitalization of $23.10 billion, a P/E ratio of 30.68, a P/E/G ratio of 1.76 and a beta of 0.78.

Labcorp (NYSE:LH) last announced its quarterly earnings results on Thursday, July 24th. The medical research company reported $4.35 EPS for the quarter, topping the consensus estimate of $4.14 by $0.21. Labcorp had a net margin of 5.66% and a return on equity of 15.45%. The firm had revenue of $3.53 billion for the quarter, compared to analyst estimates of $3.49 billion. During the same period last year, the business earned $3.94 EPS. Labcorp’s revenue for the quarter was up 9.6% compared to the same quarter last year. Labcorp has set its FY 2025 guidance at 16.050-16.500 EPS. As a group, sell-side analysts predict that Labcorp Holdings Inc. will post 16.01 earnings per share for the current fiscal year.

Labcorp Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, September 11th. Shareholders of record on Thursday, August 28th will be paid a $0.72 dividend. This represents a $2.88 dividend on an annualized basis and a yield of 1.0%. Labcorp’s dividend payout ratio is presently 31.79%.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently weighed in on the stock. Morgan Stanley raised their price objective on shares of Labcorp from $283.00 to $306.00 and gave the company an “overweight” rating in a report on Friday, July 25th. Evercore ISI raised their price objective on shares of Labcorp from $285.00 to $300.00 and gave the company an “outperform” rating in a report on Friday, July 25th. Robert W. Baird raised their price objective on shares of Labcorp from $290.00 to $302.00 and gave the company an “outperform” rating in a report on Friday, July 25th. Wall Street Zen upgraded shares of Labcorp from a “hold” rating to a “buy” rating in a report on Saturday, July 26th. Finally, Barclays restated a “cautious” rating on shares of Labcorp in a report on Wednesday, June 25th. Nine investment analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Labcorp currently has an average rating of “Moderate Buy” and a consensus price target of $289.58.

Insider Buying and Selling

In other Labcorp news, EVP Der Vaart Sandra D. Van sold 3,903 shares of Labcorp stock in a transaction on Wednesday, August 13th. The shares were sold at an average price of $271.42, for a total value of $1,059,352.26. Following the transaction, the executive vice president directly owned 2,274 shares in the company, valued at approximately $617,209.08. The trade was a 63.19% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Dwight Gary Gilliland sold 2,000 shares of Labcorp stock in a transaction on Wednesday, July 30th. The shares were sold at an average price of $264.95, for a total transaction of $529,900.00. Following the completion of the transaction, the director owned 6,656 shares in the company, valued at approximately $1,763,507.20. This represents a 23.11% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 18,046 shares of company stock valued at $4,831,192 in the last quarter. Corporate insiders own 0.84% of the company’s stock.

Labcorp Profile

Labcorp Holdings, Inc engages in providing medical testing services. The company was founded on April 16, 2024 and is headquartered in Burlington, NC.